Cardiff Oncology, Inc.
DE ˙ DB ˙ US14147L1089
1,13 € ↓ -0,10 (-7,78%)
2026-06-04
DEL PRIS
SecurityDE:XE7C / Cardiff Oncology, Inc.
InstitutionAvestar Capital, LLC
Latest Disclosed Ownership136,145 shares
Latest Disclosed Value $ 220,555
Avestar Capital, LLC ownership in XE7C / Cardiff Oncology, Inc.

On May 13, 2026 - Avestar Capital, LLC filed a 13F-HR form disclosing ownership of 136,145 shares of Cardiff Oncology, Inc. (DE:XE7C) valued at $178,350 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 136,145 shares of Cardiff Oncology, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $153,299 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F CARDIFF ONCOLOGY COM 14147L108 136,145 0 0.00 221 -42.41 0.0142
2026-02-10 2025-12-31 13F CARDIFF ONCOLOGY COM 14147L108 136,145 -4,324 -3.08 383 32.18 0.0248
2025-11-07 2025-09-30 13F CARDIFF ONCOLOGY COM 14147L108 140,469 0 0.00 289 -34.62 0.0189
2025-08-13 2025-06-30 13F CARDIFF ONCOLOGY COM 14147L108 140,469 0 0.00 442 0.23 0.0302
2025-05-14 2025-03-31 13F CARDIFF ONCOLOGY COM 14147L108 140,469 0 0.00 441 -27.59 0.0383
2025-01-29 2024-12-31 13F CARDIFF ONCOLOGY COM 14147L108 140,469 0 0.00 610 62.40 0.0518
2024-11-13 2024-09-30 13F CARDIFF ONCOLOGY COM 14147L108 140,469 0 0.00 375 20.58 0.0386
2024-08-08 2024-06-30 13F CARDIFF ONCOLOGY COM 14147L108 140,469 140,469 312 0.0320
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.